Alector, Inc. announced the termination of its collaboration and license agreement with GSK, effective January 2, 2027, following clinical trial failures for latozinemab and nivisnebart. Additionally, the company repaid in full and terminated its loan and security agreement with Hercules Capital, Inc., paying an aggregate principal amount of $10,428,827.77 plus interest and charges. Alector, Inc. is a biotechnology company focused on developing investigational monoclonal antibodies for neurodegenerative diseases.